Selective urokinase (uPA) inhibitor (IC50
= 8.2 μ
M). Exhibits no activity at 8 other related enzymes. Inhibits clot lysis with no effect on clot formation. Also decreases viability of MDA-MB231 breast cancer cells in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Elucidating novel urokinase-type plasminogen activator inhibitors.
Smith et al.
Int.Soc.Thromb.Haemost. (Abstract), 2011;9:819
Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells
Longo et al.
The citations listed below are publications that use Tocris products. Selected citations for BC 11 hydrobromide include:
Showing Results 1 - 1 of 1